Research Article

Impairment on Cardiopulmonary Function after Marathon: Role of Exhaled Nitric Oxide

Ana Paula Sierra ^(b),^{1,2} Manoel Carneiro Oliveira-Junior ^(b),³ Francine Maria Almeida,⁴ Marino Benetti,¹ Rodrigo Oliveira,⁵ Soraia Nogueira Felix,⁴ Isabella Santos Genaro,⁴ Beatriz Mangueira Saraiva Romanholo,⁴ Nabil Ghorayeb,² Maria Augusta Peduti Dal Molin Kiss,¹ Maria Fernanda Cury-Boaventura ^(b),⁵ João Bosco Pesquero,⁶ and Rodolfo Paula Vieira ^(b),^{7,8,9,10}

¹School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil

²Sports Cardiology Department, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil

³Nove de Julho University, São Paulo, Brazil

⁴Laboratory of Experimental Therapeutic (LIM 20), School of Medicine, University of São Paulo, São Paulo, Brazil

⁵Institute of Physical Activity and Sports Sciences (ICAFE), Cruzeiro do Sul University (UNICSUL), São Paulo, Brazil ⁶Department of Biophysics, Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil

⁷Post Graduation Program in Bioengenering and in Biomedical Engineering, Universidade Brasil, São Paulo, Brazil

⁸Post Graduation Program in Sciences of Human Movement and Rehabilitation, Federal University of São Paulo (UNIFESP), Santos, Brazil

⁹Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology (IBEPIPE), São José dos Campos, Brazil ¹⁰School of Medicine, Anhembi Morumbi University, São José dos Campos, Brazil

Correspondence should be addressed to Ana Paula Sierra; anasierra@usp.br

Received 18 September 2018; Accepted 8 January 2019; Published 17 February 2019

Academic Editor: Vladimir Jakovljevic

Copyright © 2019 Ana Paula Sierra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The endurance exercise is capable of inducing skeletal muscle, heart, and respiratory fatigue, evidenced by morphofunctional cardiac changes, release of myocardial injury biomarkers, and reduction of maximal voluntary ventilation and oxygen consumption (VO_2) at peak exercise. Purpose. The aim of this study was to investigate whether maratheners present cardiac fatigue after marathon and whether it correlates with pulmonary levels of exhaled nitric oxide (eNO) and pulmonary inflammation. Methods. 31 male marathoners, age 39 ± 9 years, were evaluated by cardiopulmonary exercise test three weeks before and between three and 15 days after a marathon; eNO analysis and spirometry were evaluated before, immediately after, and 24 and 72 hours after the marathon, and sputum cellularity and cytokine level were assessed before and after the marathon. Results. Marathon induced an increase in the percentage of macrophages, neutrophils (from 0.65% to 4.28% and 6.79% to 14.11%, respectively), and epithelial cells and a decrease in cytokines in induced sputum, followed by an increase in eNO concentration $(20 \pm 11 \text{ to } 35 \pm 19 \text{ ppb})$, which presented a significant reduction 24 and 72 hours after marathen $(9 \pm 12 \text{ e } 12 \pm 9 \text{ ppb}, p < 0.05)$. We observed a decrease in the spirometry parameters in all time points assessed after the marathon (p < 0.05) as well as in cardiopulmonary capacity, evidenced by a reduction in VO₂ and ventilation peaks (57 ± 6 to 55 ± 6 mL·min⁻¹·Kg⁻¹ and 134 ± 19 to 132 ± 18 Lpm, respectively, p < 0.05). Finally, we observed a negative correlation between the decrease in forced expiratory volume and decrease in eNO 24 and 72 hours after marathon (r = -0.4, p = 0.05). Conclusion. Reduction in eNO bioavailability after marathon prevents the reduction in cardiopulmonary capacity induced by acute inflammatory pattern after marathon.

1. Introduction

Previous studies indicated the oxygen transport to the muscle as a major factor to endurance exercise performance. Impairment of this process reduces VO_{2max} , compromises endurance performance, and can promote the fatigue development and decrease in cardiopulmonary function [1]. The "oxygen hypothesis" claims that after prolonged strenuous exercise, there is a reduction in oxygen gas exchange and reduction in oxygen perfusion capacity in the skeletal muscle periphery due to a reduced diffusion capacity [2].

The exhaled nitric oxide (eNO) is centrally involved in the regulation of pulmonary gas exchange [3] and in oxygen perfusion in muscle periphery [4]. In fact, a study has demonstrated that reduced levels of eNO correlates with increased exercise intolerance and with impairment on ventilatory response [3]. eNO is considered a valuable marker of airway inflammation, especially in respiratory diseases, such as asthma [5], chronic obstructive pulmonary disease [6, 7], acute respiratory distress syndrome [8], and in idiopathic pulmonary fibrosis [5–9].

Air pollution also may influence airway inflammation response during exercise [10]. Previous studies suggest that particulate matter induces oxidative and nitrosative stress as a result of superoxide and nitric oxide reaction, which downregulate NO synthase and reduces NO availability, consequently leading to vasoconstriction [11, 12].

The level of eNO has been reported to associate with bronchoconstriction and reduction on pulmonary function, especially in forced expiratory volume in 1 second (FEV1) during exercise, as a result of inflammation and flow limitations [13–15].

Therefore, the present study was aimed at investigating whether marathon causes cardiac fatigue and, if it is the case, whether cardiac fatigue correlates with pulmonary levels of eNO and pulmonary inflammation.

2. Methods

2.1. Subjects. Thirty-one male marathoners (age 39 ± 9 years) participated in the XXI São Paulo International Marathon, held on May 17th 2015. All individuals were aware of the possible risks involved in the study and provided a written informed consent. The study conformed to the declaration of Helsinki and the protocol was approved in advance by the institutional ethics committee of Dante Pazzanese Institute of Cardiology and of School of Physical Education and Sport. The exclusion criteria included the use of medication to cardiac, metabolic, pulmonary, or kidney injury, use of alcohol or any kind of drugs, and pathologies including systemic arterial hypertension and liver, kidney, metabolic, inflammatory, or neoplasic diseases.

2.2. Cardiopulmonary Test. The cardiopulmonary tests were performed from three weeks to two days before and from three days to fifteen days after marathon using a ramp protocol. The protocol began with 8 km/h and 1% fixed slope, increasing 1 km/h per minute until maximal exhaustion of the marathoner. Expired gas analysis was performed in a breath-by-breath system (Ergostik®, Geratherm, Bad

Kissingen, Germany). Room conditions were controlled and temperature was maintained between 21°C and 23°C. Air humidity was registered by a system (Ambistik®, Bad Kissingen, Germany). System was calibrated manually using a 3-liter syringe in the beginning of the section and every two tests.

2.3. Spirometry. Pulmonary function was measured using a *Spirostik*®(Geratherm, Bad Kissingen, Germany) spirometer by a trained technician 24 h before, immediately after, and 24 hours and 72 hours after marathon to obtain the parameters forced vital capacity (FVC), forced expiratory volume in one second (FEV1), the relation FEV1/FVC, and peak of expiratory flow (PEF), considering the criteria for acceptability and reproducibility, according to the recommendations of European Respiratory Society and the guidelines for pulmonary function test.

2.4. Nitric Oxide in Exhaled Air. Nitric oxide in exhaled air was measured 24 h before, immediately after, and 24 hours and 72 hours after marathon. For this procedure, we used a flow valve, an attached nozzle, and a 1.5-litter Mylar bag. The marathoners performed a controlled expiration of 12 liters per minute (controlled by the values shown in the flow valve) for eight seconds, after which the Mylar bag was quickly closed. After the procedure, the flask was emptied in the nitric oxide analyser (NO Analyzer, GE, Sievers), which uses the chemiluminescence technique to measure nitric oxide in exhaled air. System was calibrated with a cylinder with known nitric oxide concentration.

2.5. Cellularity and Cytokines in Induced Sputum. Sputum was induced by inhalation of hypertonic saline aerosol. Marathoners were instructed to blow their noses and rinse their mouths out with water, inhale nebulized 3% saline for 10 minutes, and then instructed to expectorate their sputum into sterile pots. Sputum was separated from contaminants and saliva, placed in a centrifugal tube, and centrifuged for 10 min at 1200 g at 4°C. The supernatant was collected and stored at -80°C. Total cell numbers was determined by cell counting using a hemocytometer (Neubauer chamber) and differential cell counting by cytospin preparations stained with Diff-Quik staining, where 300 cells were analysed and counted according to the haematological and morphological criteria in a blinded fashion for individual and time point description.

The concentrations of cytokines were measured using ELISA kits (DuoSet, R&D Systems, MN USA), according to the manufacturer's instructions.

2.6. Statistical Analysis. Statistical analysis was performed in SPSS software 22.0 (IBM Inc., Chicago IL, 2013). Kolmogorov-Smirnov test was performed and the data rejected normality in most variables. To analyse the marathon's impact on data during the four steps, we performed Friedman test and Müller-Dunn post test for variables that have more than two moments. For the variables with two moments, we performed Wilcoxon test. Spearman correlation test was applied to identify the correlation between the

TABLE 1: Demographic characteristics and marathon time of marathoners (n = 31).

Variable	Mean±standard deviation
Age (years)	39 ± 9
Marathon time (minutes)	270 ± 40
Average speed (km/h)	9.5 ± 0.2
% of CPET peak speed	51.9 ± 0.1
Running volume (km)	57 ± 23

Data are shown in mean±standard deviation. Percentage of peak speed=average speed during marathon/peak speed in cardiopulmonary test *100, CPET: cardiopulmonary exercise test.

TABLE 2: Inflammatory cells and cytokines after marathon in sputum.

	Before	Immediately after
Total cells (×10 ⁴ /mL)	143 ± 16	$266^* \pm 43$
Neutrophils (×10 ⁴ /mL)	13 ± 10	$61^* \pm 13$
Macrophages (×10 ⁴ /mL)	21 ± 6	$54^{*} \pm 14$
Epithelial cells (×10 ⁴ /mL)	113 ± 12	$201^* \pm 32$
Lymphocytes (×10 ⁴ /mL)	79 ± 221	53 ± 82
IL-6 (pg/mL)	581 ± 1529	87 ± 53
IL-8 (pg/mL)	3099 ± 6511	1450 ± 6233
IL-12p40 (pg/mL)	3775 ± 12406	$285^{*} \pm 131$
IL-23 (pg/mL)	3722 ± 12115	$1004^*\pm254$
IL-33 (pg/mL)	412 ± 1546	$267^{*} \pm 145$
TSLP (pg/mL)	387 ± 1974	$20^{*} \pm 16$

Data are shown in mean±standard deviation. *p < 0.05. IL: interleukin.

variables. The results are shown in mean values and standard deviation. The significance level was set to 5%.

3. Results

Thirty-one marathoners completed the São Paulo International Marathon and all of the steps of this study. The marathon took place in fall and day was sunny throughout the marathon (temperature between 16.1°C and 22.6°C and humidity between 89% and 61%). Demographic characteristics and marathon time are shown in Table 1.

3.1. Increased Airway Inflammation after Marathon. Immediately after the marathon race, the number of macrophages, neutrophils, and epithelial and total cells increased in sputum by 2.5-fold, 4.7-fold, 1.8-fold, and 1.8-fold, respectively (p < 0.01). Macrophage percentage changed from 0.65% to 4.28% and neutrophil percentage from 6.79% to 14.11%. Lymphocyte percentage did not show significant changes after marathon (Table 2). In addition, marathon race reduced IL-12p40 (p < 0.01), IL-23 (p < 0.03), IL-33 (p < 0.01), and thymic stromal lymphopoietin (TSLP) levels (p < 0.05). However, IL-6 and IL-8 did not show significant changes after marathon compared with basal levels (Table 2). 3.2. Changes in Exhaled Nitric Oxide (eNO) after Marathon. Exhaled NO increased immediately after the marathon and reduced 24 hours and 72 hours after the race (Figure 1).

3.3. Decreased Cardiopulmonary Function after Marathon. Values for FVC, FEV1, and PEF were decreased after marathon and did not return to baseline levels, suggesting an impairment of pulmonary function until three days after the race (Table 3).

The cardiopulmonary function presented a significant decrease in a period after marathon (three to fifteen days after marathon) especially concerning VO_2 peak, ventilation peak, and $PetO_2$ peak, even though the marathoners have reached the same speed in both tests, as shown in Table 4.

We observed a positive correlation between the amount of eNO and the number of macrophages in sputum immediately after marathon (r = 0.573, p < 0.01) suggesting pulmonary inflammation. Moreover, a negative correlation between the differences in FEV1 72 hours with the difference in nitric oxide values 24 and 72 hours after marathon (r = -0.4, p < 0.05) was found. Finally, we found a positive correlation between FVC and peak VO₂ values after marathon (r = 0.421, p < 0.05).

4. Discussion

The major finding of this study was the impairment of pulmonary function and VO_{2peak} , associated to airway inflammation, marked by increased levels of exhaled nitric oxide and inflammatory cell number in the sputum of marathoners after a marathon. The bioavailability of exhaled nitric oxide was negatively associated to pulmonary function and with cardiac fatigue after marathon.

Our study showed an increase in epithelial cell number in induced sputum after marathon, suggesting airway injury characterized by epithelial desquamation. Airway epithelial cells protect the airways against external agents, not only by acting as a physical and functional barrier but also by modulating airway inflammation and repair processes [16, 17].

Airway inflammation in athletes has been poorly described and with controversial results in studies focusing this subject [18, 19]. Bonsignore et al. found increases in lymphocytes and eosinophils and a decrease in macrophages in induced sputum after a 5 km race at the beach [20]. Conversely, and in accordance with our study, Larsson et al. observed an increase in inflammatory cells expressed by neutrophils and macrophages in subjects which performed one hour of exercise on a treadmill [21].

Chimenti et al. suggest that increases in inflammatory cells in the airways do not necessarily imply the occurrence of proinflammatory activation because the markers of inflammation in induced sputum were not increased [17]. In addition, we suggest that reduced levels of important airway cytokines impair the pulmonary immune function preventing the resolution of inflammation. IL-12 is a cytokine important in host immunity, produced by activated macrophages, neutrophils, and dendritic cells. The p40 subunit of IL-12 is shared by IL-23, promoting the differentiation of Th1 and Th17 cells, respectively. A previous study suggested




FIGURE 1: Exhaled nitric oxide before, immediately after, and 24 hours and 72 hours after marathon (ppb).

TABLE 3: Pulmonary function before, immediately after, and 24 hours and 72 hours after marathon.

	24 h before	Immediately after	24 h after	72 h after
FVC (L)	4.9 ± 0.7	$4.6\pm0.7^*$	$4.8\pm0.7^*$	$4.8\pm0.7^*$
FEV1 (L)	3.9 ± 0.6	$3.8\pm0.7^{*}$	$3.7\pm0.7^*$	$3.8\pm0.6^*$
PEF (L/s)	10.07 ± 1.9	$8.96\pm2.1^*$	$9.17\pm2^*$	$9.36 \pm 1.9^*$
FEV1/FVC	80.9 ± 5.5	81.5 ± 6.4	78.5 ± 9.3	$78.8\pm6.9^*$

Data are shown in mean±standard deviation. FVC: forced vital capacity; FEV1: forced expiratory volume in one second; PEF: peak of expiratory flow. *p < 0.05 compared with basal values.

 TABLE 4: Cardiopulmonary function behaviour before and after marathon.

Variable	Before marathon	After marathon	<i>p</i> value
HR at rest (bpm)	67 ± 9	65 ± 16	NS
Peak HR (bpm)	182 ± 13	181 ± 14	NS
Peak speed (km/h)	18 ± 2	18 ± 3	NS
Peak VO ₂ (mL·kg ⁻¹ ·min ⁻¹)	57 ± 6	55 ± 6	*<0.01
Peak VE (L/min)	134 ± 19	132 ± 19	*<0.05
O ₂ pulse (mL·btm)	22 ± 3	22 ± 3	NS
Peak PetO ₂	111 ± 6	114 ± 4	*<0.05
VE/VCO ₂ slope	26 ± 3	26 ± 2	NS

Data are shown in mean±standard deviation. HR: heart rate; VO₂: oxygen consumption; VE: ventilation; O₂: oxygen; PetO₂: end-tidal oxygen tension.

that IL-12p40 may be indispensable for downregulation of airway fibrosis and inflammation [22]. In addition, the downregulation of IL12p40 is associated with Th2 induction [23]. However, downregulation of IL-33 and thymic stromal lymphopoietin (TSLP) reduces Th2 differentiation, suggesting an imbalance on airway immune response. These cytokines are proallergenic indicating also low allergenic response as well as impaired airway immune function after marathon running [24]. On the other side, it has been demonstrated that low and moderate intensity aerobic exercise can result in opposite effects in comparison with marathon running, restoring airway immunological balance, although epithelial desquamation persists [25].

In our study, we found increase in eNO immediately after marathon with significant decrease 24 and 72 hours after marathon, with a reduction in bioavailability of eNO in this period. Accordingly, Carbonnelle et al. [26] and De Gouw et al. [27] found an increase in eNO levels after two sessions of swimming and after cycling, respectively. A direct relationship between acute exercise intensity and the levels of eNO in sedentary healthy and trained subjects has also been reported [16]. However, assessment of nitric oxide concentrations has shown controversial results, with some researchers reporting a decrease in eNO during exercise in sedentary and active subjects, paralleled with an increased VO_2 and ventilation. As yet, the behaviour of eNO some days after marathon has not been studied previously.

Another important finding in this study is the decrease in pulmonary function, as evidenced by FEV1, FVC, and PEF after marathon, which was sustained until 72 hours after marathon. In fact, it has been reported that respiratory muscles significantly fatigue during endurance activities such as the marathon, reducing maximal voluntary and expiratory pressures and peak inspiratory and expiratory flow rates [28].

The lungs have crucial role in gas exchange, experiencing great modifications of their activity during exercise, in addition to their important role in cardiopulmonary function [19]. Miles et al. [29] have reported a reduction in pulmonary diffusing capacity after prolonged exercise, which persisted for a certain period of time.

Finally, we found the so-called sport cardiac fatigue evidenced by a decrease in VO₂ peak. In previous studies, we demonstrated a postmarathon drop in VO₂ peak and O₂ pulse, which is consistent with reduction in cardiac inotropism, but with pulmonary compensation, with greater ventilatory efficiency and optimization of O₂ use to achieve the same exertion [2]. However, in this study, we also could observe a decrease in VO₂ and VE peaks, bringing about an important cardiac fatigue without pulmonary compensation, which could possibly be explained by the increased pulmonary inflammation evidenced by an increase in inflammatory cells and eNO after marathon, with a decrease in cytokines, as explained above. Nevertheless, the important negative correlation between FEV1 and nitric oxide levels 24 and 72 hours after marathon and the positive correlation between FVC and VO_2 peak after marathon suggest an adaptation of some athletes in reducing the bioavailability of eNO and maybe increasing pulmonary immunity to maintain cardiopulmonary capacity and reduce cardiac fatigue.

5. Conclusion

In summary, the present study shows an increase in nitric oxide in exhaled air and in inflammatory cell number, as well as a decrease in cytokines in sputum in marathoners after marathon running, which reflects an airway inflammation and impairment of the airway immune system, which in turn hinders cardiopulmonary capacity. However, those athletes who presented a lower eNO bioavailability presented a lower decrease in the cardiopulmonary capacity and in cardiac fatigue, highlighting the role of eNO in these parameters, as a plausible mechanism involved in this response.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

The opinion, hypothesis, and conclusions or recommendations expressed in this material are responsibility of the authors and does not reflect, necessarily, the vison of FAPESP. Part of this project has been presented as conference abstract in the World Congress of Sports Medicine in Revista Brasileira de Medicina do Esporte.

Conflicts of Interest

The authors declare that none of them have conflict of interest and the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.

Acknowledgments

The authors are indebted to Yescom and IDEEA institute for assistance in São Paulo International Marathon, TEB, Geratherm and AFIP for technical assistance. This study was supported by São Paulo Research Foundation (FAPESP) grant # 2012/15165-2 and # 2014/21501-0 and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). MCOJ holds a PhD fellowship from FAPESP (2014/14604-8).

References

- M. Amann and J. A. Calbet, "Convective oxygen transport and fatigue," *Journal of Applied Physiology*, vol. 104, no. 3, pp. 861– 870, 2008.
- [2] A. P. Sierra, A. D. Silveira, R. C. Francisco et al., "Reduction in post-marathon peak oxygen consumption: sign of cardiac fatigue in amateur runners?," *Arquivos Brasileiros de Cardiologia*, vol. 106, no. 2, pp. 92–96, 2016.

- [3] H. Adachi, S. Oshima, S. Sakurai et al., "Nitric oxide exhalation correlates with ventilatory response to exercise in patients with heart disease," *European Journal of Heart Failure*, vol. 5, no. 5, pp. 639–643, 2003.
- [4] D. P. Casey and M. J. Joyner, "Local control of skeletal muscle blood flow during exercise: influence of available oxygen," *Journal of Applied Physiology*, vol. 111, no. 6, pp. 1527–1538, 2011.
- [5] S. R. Mummadi and P. Y. Hahn, "Update on exhaled nitric oxide in clinical practice," *Chest*, vol. 149, no. 5, pp. 1340– 1344, 2016.
- [6] X. Liu, G. Wu, D. Shi et al., "Effects of nitric oxide on notexin-induced muscle inflammatory responses," *International Journal of Biological Sciences*, vol. 11, no. 2, pp. 156– 167, 2015.
- [7] G. Santini, N. Mores, R. Shohreh et al., "Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers," *Journal of Breath Research*, vol. 10, no. 1, article 017102, 2016.
- [8] C. Sittipunt, K. P. Steinberg, J. T. Ruzinski et al., "Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome," *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 2, pp. 503–510, 2001.
- [9] L. Guilleminault, A. Saint-Hilaire, O. Favelle et al., "Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?," *Respiratory Medicine*, vol. 107, no. 11, pp. 1789–1796, 2013.
- [10] M. Sehlstedt, A. F. Behndig, C. Boman, A. Blomberg, T. Sandström, and J. Pourazar, "Airway inflammatory response to diesel exhaust generated at urban cycle running conditions," *Inhalation Toxicology*, vol. 22, no. 14, pp. 1144– 1150, 2010.
- [11] K. W. Rundell, J. B. Slee, R. Caviston, and A. M. Hollenbach, "Decreased lung function after inhalation of ultrafine and fine particulate matter during exercise is related to decreased total nitrate in exhaled breath condensate," *Inhalation Toxicology*, vol. 20, no. 1, pp. 1–9, 2008.
- [12] K. W. Rundell, J. M. Smoliga, and V. Bougault, "Exercise-induced bronchoconstriction and the air we breathe," *Immunology and Allergy Clinics of North America*, vol. 38, no. 2, pp. 183–204, 2018.
- [13] I. Chinellato, M. Piazza, D. Peroni et al., "Bronchial and alveolar nitric oxide in exercise-induced bronchoconstriction in asthmatic children," *Clinical and Experimental Allergy*, vol. 42, no. 8, pp. 1190–1196, 2012.
- [14] R. A. Dweik, P. B. Boggs, S. C. Erzurum et al., "An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications," *American Journal of Respiratory and Critical Care Medicine*, vol. 184, no. 5, pp. 602–615, 2011.
- [15] S. R. Downie, C. M. Salome, S. Verbanck, B. Thompson, N. Berend, and G. G. King, "Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation," *Thorax*, vol. 62, no. 8, pp. 684–689, 2007.
- [16] Y. Tesfaigzi, "Roles of apoptosis in airway epithelia," American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 5, pp. 537–547, 2006.
- [17] L. Chimenti, G. Morici, A. Paternò et al., "Environmental conditions, air pollutants, and airway cells in runners: a

longitudinal field study," Journal of Sports Sciences, vol. 27, no. 9, pp. 925–935, 2009.

- [18] E. C. Gomes, V. Stone, and G. Florida-James, "Impact of heat and pollution on oxidative stress and CC16 secretion after 8 km run," *European journal of applied physiology*, vol. 111, no. 9, pp. 2089–2097, 2011.
- [19] O. F. Araneda, T. Carbonell, and M. Tuesta, "Update on the mechanisms of pulmonary inflammation and oxidative imbalance induced by exercise," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 4868536, 23 pages, 2016.
- [20] M. R. Bonsignore, G. Morici, L. Riccobono et al., "Airway cells after swimming outdoors or in the sea in nonasthmatic athletes," *Medicine & science in sports & exercise*, vol. 35, no. 7, pp. 1146–1152, 2003.
- [21] K. Larsson, G. Tornling, D. Gavhed, C. Muller-Suur, and L. Palmberg, "Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects," *European Respiratory Journal*, vol. 12, no. 4, pp. 825–830, 1998.
- [22] Y. Onari, A. Yokoyama, Y. Haruta et al., "IL-12p40 is essential for the down-regulation of airway hyperresponsiveness in a mouse model of bronchial asthma with prolonged antigen exposure," *Clinical & Experimental Allergy*, vol. 39, no. 2, pp. 290–298, 2009.
- [23] T. P. Moran, K. Nakano, G. S. Whitehead, S. Y. Thomas, D. N. Cook, and H. Nakano, "Inhaled house dust programs pulmonary dendritic cells to promote type 2 T-cell responses by an indirect mechanism," *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 309, no. 10, pp. L1208–L1218, 2015.
- [24] B. N. Lambrecht and H. Hammad, "Allergens and the airway epithelium response: gateway to allergic sensitization," *The Journal of Allergy and Clinical Immunology*, vol. 134, no. 3, pp. 499–507, 2014.
- [25] R. P. Vieira, A. C. Toledo, S. C. Ferreira et al., "Airway epithelium mediates the anti-inflammatory effects of exercise on asthma," *Respiratory Physiology & Neurobiology*, vol. 175, no. 3, pp. 383–389, 2011.
- [26] S. Carbonnelle, A. Bernard, I. R. Doyle, J. Grutters, and M. Francaux, "Fractional exhaled NO and serum pneumoproteins after swimming in a chlorinated pool," *Medicine and science in sports and exercise*, vol. 40, no. 8, pp. 1472–1476, 2008.
- [27] H. W. De Gouw, S. J. Marshall-Partridge, H. Van Der Veen, J. G. Van Den Aardweg, P. S. Hiemstra, and P. J. Sterk, "Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects," *Journal of Applied Physiology*, vol. 90, no. 2, pp. 586–592, 2001.
- [28] J. J. Salinero, M. L. Soriano, D. Ruiz-Vicente et al., "Respiratory function is associated to marathon race time," *The Journal* of Sports Medicine and Physical Fitness, vol. 56, no. 12, pp. 1433–1438, 2016.
- [29] D. S. Miles, C. E. Doerr, S. A. Schonfeld, D. E. Sinks, and R. W. Gotshall, "Changes in pulmonary diffusing capacity and closing volume after running a marathon," *Respiration physiology*, vol. 52, no. 3, pp. 349–359, 1983.